Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-01-22 Capital/Financing Update
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering
Capital/Financing Update Classification · 98% confidence The document is titled "INFORMATION DOCUMENT" concerning a "SUBSEQUENT OFFERING" of new shares by Oncoinvent ASA, detailing the subscription price, timetable, and procedures for exercising Subscription Rights. This document explicitly states its purpose is to provide information about a capital raising/financing activity (issuing new shares for proceeds). This aligns directly with the definition of a Capital/Financing Update (CAP). Although it is a detailed document (63k characters), its core subject is the mechanics of a share issuance/offering, not a periodic financial report (10-K, IR) or a general announcement of a report (RPA).
2025-01-22 English
Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering
Capital/Financing Update Classification · 98% confidence The document explicitly discusses a 'Resolution to increase the share capital in connection with subsequent offering' and details the issuance of new shares, subscription prices, and a subscription period. This directly relates to fundraising, financing activities, and changes in the capital structure. The key phrases are 'increase the share capital', 'subsequent offering', and 'subscription price'. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it mentions a general meeting resolution, the primary focus is the capital raise mechanism, not the voting results (DVA) or the general meeting presentation (AGM-R).
2025-01-22 English
Annual Report 2023
Annual Report Classification · 100% confidence The document explicitly states in the title and content that it is the "Annual Report 2023". It contains a detailed Table of Contents listing sections typical of a comprehensive annual filing, such as 'Director's report', 'Financial statement', 'Statement of profit and loss and comprehensive income', and 'Statement of financial position'. The length (over 160,000 characters) also confirms it is a full report, not a brief announcement. This directly corresponds to the definition of an Annual Report (10-K equivalent for non-US filers, but classified under our internal code for comprehensive annual reports). FY 2023
2024-05-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.